Wall Street analysts who monitor the makers of these implantabledefibrillators - companies such as Boston Scientific, Medtronic and St. Jude Medical - paid heed to the new study.
The same may also be true for patients with implantable cardioverter defibrillators who have a history of ventricular tachycardia and who are not taking antiarrhythmic medications.